MTOR and bladder transitional cell carcinoma: Finally, potential druggable targets and corresponding compounds for BLCA patients were identified from the GDSC and CTRP databases in light of developed prognostic models, primarily including cell cycle (staurosporine and RO-3306), PI3K/mTOR pathway (XL765, TGX-221, AZD8186, and AZD8055) and Wnt pathway inhibitors (CCT036477 and SB216763), which were compatible with the pathway enrichment results of DEGs.